13th International Conference on Myasthenia Gravis and Related Disorders

15–17 May 2017
New York, United States
 
The treatment for myasthenia gravis (MG) — a rare, acquired autoimmune syndrome resulting in severe muscle weakness and fatigue, significant disability, and decreased life expectancy — has improved dramatically in the last several decades. While modern medical advances have reduced MG mortality rates over the last several decades, there has been an increase in reported cases especially among the aging population. The number of diagnosed MG cases is expected to rise as the aging population increases and screening techniques for MG improve. From a public health perspective it is clear that increased understanding of the etiology underlying MG is critical for enhancing diagnosis and treatment of this disease. To better translate basic research discoveries into the standard treatment regimen of MG patients, the New York Academy of Sciences, in partnership with the Myasthenia Gravis Foundation of America, will organize the 13th International Conference on Myasthenia Gravis and Related Disorders.

Keynote Speaker: 
Vijay K. Kuchroo (Harvard Institutes of Medicine)

Call for Abstracts and Travel Fellowship Applications: 
The deadline for abstract submissions and applications is March 13, 2017.

Related Events

Comments